BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2697430)

  • 1. Graft-versus-host disease: effects on long term disease free survival in marrow transplantation for haematological malignancies.
    Kapoor N; Copelan EA; Klein J; Tutschka PJ
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():153-5. PubMed ID: 2697430
    [No Abstract]   [Full Text] [Related]  

  • 2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
    Przepiorka D; Ippoliti C; Giralt S; van Beisen K; Mehra R; Deisseroth AB; Andersson B; Luna M; Cork A; Lee M
    Bone Marrow Transplant; 1994 Sep; 14(3):449-53. PubMed ID: 7994271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of leukemia by marrow transplantation from HLA incompatible donors. Effect of HLA-disparity on GVHD, relapse and survival.
    Hansen JA; Anasetti C; Beatty PG; Martin PJ; Sanders JE; Storb R; Thomas ED
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():108-11. PubMed ID: 2390636
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for ALL in Zagreb.
    Bogdanić V; Labar B; Nemet D; Mrsić M; Pavetić Z; Aurer I
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():88-9. PubMed ID: 2697414
    [No Abstract]   [Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
    Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):441-7. PubMed ID: 1821620
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
    Copelan EA; Penza SL; Elder PJ; Belt PS; Scholl MD; Hehmeyer DM; Ezzone SA; Bechtel TP; Avalos BR
    Bone Marrow Transplant; 1996 Nov; 18(5):907-11. PubMed ID: 8932844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
    Mrsić M; Nemet D; Labar B; Bogdanić V; Radman I; Zupancić-Salek S; Kovacević-Metelko J; Aurer I; Maravić N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1268-70. PubMed ID: 8442109
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone marrow transplantation and graft-versus-host disease.
    Powles RL
    Curr Opin Immunol; 1989-1990; 2(6):870-5. PubMed ID: 2486567
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
    von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
    Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.
    Rizzoli V; Carella AM; Carlo-Stella C; Mangoni L
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():76-8. PubMed ID: 2202474
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic BMT for AML in Zagreb.
    Labar B; Bogdanić V; Nemet D; Mrsić M; Pavletić Z; Zupancić S; Radman I; Aurer I
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():86-7. PubMed ID: 2697413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.